afutuzumab |
9043 |
99 (2008) |
|
GA101 |
|
Humanized |
|
9043 |
|
IgG1κ
|
|
MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35)
[Homo sapiens]
|
Mus musculus |
B-ly1 |
Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) |
Non-Hodgkin's B cell lymphoma (NHL) |
|
|
|
|
|
|
|
|
|
|
[p]
|
alacizumab pegol |
8976 |
98 (2007) |
60 (2008) |
CDP791, g165 DFM-PEG |
|
Humanized |
|
8976 |
|
Fab'
|
|
KDR (kinase insert domain receptor; VEGFR2, Vascular endothelial growth factor receptor 2; VEGF-R2; FLK1; CD309)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) |
Unknown |
|
|
|
|
|
|
|
|
|
|
|
alemtuzumab |
8005 |
83 (2000) |
45 (2001) |
Campath-1H, LDP-03 |
CAMPATH®
(US)
MABCAMPATH®
(EU)
|
Humanized |
|
8005 |
1bey 1ce1 |
IgG1κ
|
|
CD52
[Homo sapiens]
|
Rattus norvegicus |
YTH34.5HL |
Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) |
B cell chronic lymphocytic leukemia (B-CLL) |
Phase M |
FDA approval May 2001 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Immunology, Oncology |
(BLA) 103948 |
|
|
C1681 |
702 |
[a] [b] [c]
[19]
|
Kidney transplant rejection |
Phase I/II |
|
CHO (Chinese Hamster Ovary) cells |
|
|
Multiple sclerosis (MS) |
Phase I/II |
|
CHO (Chinese Hamster Ovary) cells |
|
|
anrukinzumab |
8942 |
98 (2007) |
60 (2008) |
IMA-638 |
|
Humanized |
|
8942 |
|
IgG1
|
|
IL13 (interleukin 13; IL-13)
[Homo sapiens]
|
Mus musculus |
IMA-638 |
Wyeth Pharmaceuticals (Madison NJ USA) |
Asthma |
Phase II |
|
|
|
|
|
|
|
|
|
|
apolizumab |
8210 |
87 (2002) |
49 (2003) |
|
REMITOGEN™
SMART™ 1D10
|
Humanized |
|
|
|
IgG1
|
|
HLA-DRB (HLA-DR beta)
[Homo sapiens]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
B cell chronic lymphocytic leukemia (B-CLL) (refractory) |
Phase II |
|
|
|
|
|
|
|
C2228 |
|
[b]
|
Non-Hodgkin's B cell lymphoma (NHL) |
Phase II |
|
|
|
|
bapineuzumab |
8624 |
93 (2005) |
55 (2006) |
|
|
Humanized |
|
|
|
IgG1
|
|
Beta amyloid (β-amyloid)
[Homo sapiens]
|
Mus musculus |
AAB-001 |
Wyeth Pharmaceuticals (Madison NJ USA) |
Alzheimer's disease |
Phase III |
|
|
|
|
|
|
|
|
|
|
bevacizumab |
8017 |
83 (2000) |
45 (2001) |
12-IgG1, F(ab)-12 IgG1, Fab-12 IgG1, rhuMAb-VEGF |
AVASTIN®
|
Humanized |
|
8017 |
1bj1 |
IgG1
|
|
VEGF-A (Vascular Endothelial Growth Factor A)
[Homo sapiens]
|
Mus musculus |
muMAb-VEGF A.4.6.1 |
Genentech Inc. (S. San Francisco CA USA) (EU) |
Breast cancers (metastatic HER2 negative) |
Phase M |
FDA approval February 2008 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Oncology |
(BLA) 125085 |
|
|
|
851 |
[a] [b]
(20)
|
Metastatic carcinoma of the colon and rectum |
Phase M |
FDA approval February 2004 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Oncology |
Metastatic colorectal cancers |
Phase M |
FDA approval June 2006 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Oncology |
Metastatic non-small cell lung cancers |
Phase M |
FDA approval October 2006 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Oncology |
Genentech Inc. (S. San Francisco CA USA) / NIH (Bethesda MD USA) |
Renal cancers |
Phase II |
NCI trial |
|
|
|
bivatuzumab |
7965 |
83 (2000) |
45 (2001) |
|
|
Humanized |
|
|
|
|
|
|
|
|
Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) |
Squamous cancers |
Phase I |
Market discontinued (skin toxicity) February 2005 |
|
|
|
|
|
|
|
|
|
cantuzumab mertansine |
8223 |
89 (2003) |
51 (2004) |
SB408075, huC242-DMI |
|
Humanized |
|
|
|
|
|
|
Mus musculus |
|
GlaxoSmithKline (Brentford UK) / ImmunoGen Inc. (Cambridge MA USA) |
Colorectal cancers |
Phase I/II |
|
|
|
|
|
|
|
|
|
[b]
|
Non-small-cell lung cancers |
Phase I/II |
|
|
|
|
Pancreatic cancers |
Phase I/II |
|
|
|
|
cedelizumab |
7567 |
77 (1997) |
39 (1998) |
ORTHOCLONE OKT4 A |
|
Humanized |
|
|
|
IgG
|
|
CD4 (p55)
[Homo sapiens]
|
Mus musculus |
|
Ortho Biotech Products LP (Bridgewater NJ USA) |
Treatment CD4 mediated autoimmune diseases |
Phase II |
|
|
|
|
|
|
|
|
|
[a] [b]
|
Prevention Organ transplant allograft rejection |
Phase II |
|
|
|
|
certolizumab pegol |
8448 |
90 (2004) |
52 (2004) |
CDP870, PHA-738144 |
CIMZIA®
|
Humanized |
|
|
|
PEGylated Fab'
|
|
TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) |
Crohn's disease (CD) |
Phase M |
FDA approval April 2008 |
|
|
|
(BLA) 125160 |
|
|
|
|
|
Rheumatoid arthritis (RA) |
Phase III |
|
|
|
|
citatuzumab bogatox |
9046 |
99 (2008) |
61 (2009) |
VB6-845 |
|
Humanized Immunotoxin |
Bougainvillea spectabilis Willd bouganin |
9046 |
|
Fab
|
|
EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM)
[Homo sapiens]
|
Mus musculus |
Humanized |
Viventia Biotechnologies Inc. (Mississauga ON Canada) |
Solid tumors |
Phase I |
|
|
|
|
|
|
|
|
|
|
dacetuzumab |
8959 |
98 (2007) |
60 (2008) |
SGN-40, huS2C |
|
Humanized |
|
8959 |
|
IgG1
|
|
CD40 (tumor necrosis factor receptor superfamily member 5; TNFRSF5)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) / Seattle genetics, Inc. (Bothell WA USA) |
Diffuse large B-cell lymphoma (DLBCL) |
Phase II |
|
|
|
|
|
|
|
|
|
[p]
|
Multiple myeloma |
Phase I |
|
|
|
|
Non-Hodgkin's lymphoma (NHL) |
Phase I |
|
|
|
|
daclizumab |
7164 |
78 (1997) |
40 (1998) |
|
ZENAPAX®
|
Humanized |
|
|
|
IgG1
|
|
IL2RA (interleukin-2 receptor, alpha; IL-2R; TAC; CD25)
[Homo sapiens]
|
Mus musculus |
1H4 |
F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) |
Prevention Acute kidney transplant rejection |
Phase M |
FDA approval December 1997 |
Sp2/0 mouse myeloma cells |
Therapeutic |
Immunology |
(BLA) 103749 |
|
|
C1569 |
359 |
[b] [c] [j]
[46] [50]
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Asthma |
Phase II |
|
|
|
|
Blood cancers |
Phase II |
|
|
|
|
Graft-versus-host disease (GvHD) |
Phase II |
|
|
|
|
Liver transplantation |
Phase II |
|
|
|
|
Pediatric kidney transplantation |
Phase I/II |
|
|
|
|
Psoriasis |
Phase II |
|
|
|
|
Tropical spastic paraparesis (model for multiple sclerosis) |
Phase I/II |
|
|
|
|
Ulcerative colitis |
Phase II |
|
|
|
|
Uveitis |
Phase I/II |
|
|
|
|
eculizumab |
8231 |
87 (2002) |
49 (2003) |
5G1.1 |
SOLIRIS™
|
Humanized |
|
|
|
IgG
|
|
C5 (complement 5)
[Homo sapiens]
|
Mus musculus |
|
Alexion Pharmaceuticals Inc. (New Haven CT USA) |
Dermatomyositis |
Phase I/II |
|
|
|
|
(BLA) 125166 |
|
|
C48386 |
945 |
[a] [b]
|
Nephritis |
Phase II |
|
|
|
|
Paroxysmal nocturnal hemoglobinuria (PNH) |
Phase M |
FDA approval March 2007 |
|
Therapeutic |
Unknown |
Psoriasis |
Phase I/II |
|
|
|
|
Rheumatoid arthritis (RA) |
Phase II |
|
|
|
|
efalizumab |
8122 |
85 (2001) |
47 (2002) |
hu1124 |
RAPTIVA®
|
Humanized |
|
|
|
IgG1κ
|
|
ITGAL (INTEGRIN-ALPHA-L; LFA-1, lymphocyte function associated antigen 1; CD11a)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) (EU/US) / Merck Serono International S.A. (Geneva Switzerland) (EU) / Xoma (Berkeley CA USA) (US) |
Psoriasis (infection in chronic moderate to severe plaque) |
Withdrawn |
FDA withdrawal (risk of developing progressive multifocal leukoencephalopathy) March 2009, FDA approval October 2003 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Immunology |
(BLA) 125075 |
|
|
C68831 |
|
[a] [b] [j]
|
elotuzumab |
9074 |
100 (2008) |
62 (2009) |
HuLuc63, PDL-063, PDL063 |
|
Humanized |
|
9074 |
|
IgG1κ
|
|
SLAM7 (SLAM family member 7; CD2 subset 1; CS1; CRACC, CD2-like receptor-activating cytotoxic cells; 19A24; CD319)
[Homo sapiens]
|
Homo sapiens |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Multiple myeloma |
Phase I |
|
|
|
|
|
|
|
|
|
|
epratuzumab |
7920 |
82 (1999) |
44 (2000) |
hLL2 |
LYMPHOCIDE™
|
Humanized |
radiolabelled with Yttrium-90, Y-90 |
|
|
IgG1
|
|
CD22 (BL-CAM)
[Homo sapiens]
|
Mus musculus |
|
Immunomedics Inc. (Morris Plains NJ USA) |
Non-Hodgkin's B cell lymphoma (NHL) |
Phase I/II |
|
|
|
|
|
|
|
C1887 |
|
[a] [b] [e]
|
Systemic lupus erythematosus (SLE) |
|
|
|
|
|
etaracizumab |
8862 |
99 (2008) |
61 (2009) |
MEDI-522, hLM60 |
VITAXIN®
|
Humanized |
|
8862 |
|
IgG1
|
|
ITGAV/ITGB3 (INTEGRIN-ALPHA-V_BETA-3; αvβ3; CD51/CD61; CD51/GPIIIa; CD51/platelet membrane glycoprotein IIIa; VNR, vitronectin receptor; AlphaVbeta3 integrin)
[Homo sapiens]
|
Mus musculus |
LM609 |
MedImmune Inc. (Gaithersburg MD USA) |
Metastatic melanoma |
Phase II |
|
|
|
|
|
|
|
|
|
[a]
|
Sarcoma |
Phase II |
|
|
|
|
farletuzumab |
9067 |
100 (2008) |
62 (2009) |
M3, MORAb-003 |
|
Humanized |
|
9067 |
|
IgG1κ
|
|
FOLR1 (folate receptor 1; FR-alpha, folate receptor alpha; FBP, adult folate-binding protein) ovarian tumor-associated antigen MOv18
[Homo sapiens]
|
Homo sapiens |
|
Morphotek Inc. (Exton PA USA) |
Ovarian cancers |
Phase II |
EC Orphan drug April 2008 |
|
|
|
|
|
|
|
|
|
felvizumab |
7623 |
77 (1997) |
39 (1998) |
SB 209763 |
|
Humanized |
|
|
|
IgG1
|
|
RSV (respiratory syncytial virus)
[virus]
|
Mus musculus |
|
Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) |
Treatment Respiratory Syncytial Virus (RSV) disease (Prophylaxis) |
Phase III |
|
|
|
|
|
|
|
|
|
[e]
|
fontolizumab |
8264 |
87 (2002) |
49 (2003) |
|
|
Humanized |
|
|
|
IgG1
|
|
IFNG (interferon gamma; IFN gamma)
[Homo sapiens]
|
Mus musculus |
|
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Crohn's disease (CD) |
Phase I/II |
|
|
|
|
|
|
|
|
|
|
gemtuzumab |
8024 |
83 (2000) |
45 (2001) |
CMA-676 |
MYLOTARG®
|
Humanized |
calicheamicin conjugated |
|
|
IgG4κ
|
|
CD33 (SIGLEC3; SIGLEC-3; gp67; p67)
[Homo sapiens]
|
Mus musculus |
p67,6 |
Wyeth Pharmaceuticals (Madison NJ USA) |
Acute myeloid leukemia (AML) (CD33 positive) |
Phase M |
FDA approval May 2000 |
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells |
Therapeutic |
Hematology, Oncology |
(NDA) 021174 |
|
|
|
842 |
[f] [j]
(17)
|
ibalizumab |
8818 |
97 (2007) |
59 (2008) |
Hu5A8, TNX-355 |
|
Humanized |
|
8818 |
|
IgG4
|
|
CD4 (p55)
[Homo sapiens]
|
Mus musculus |
|
Tanox Inc. (Houston TX USA) |
AIDS, HIV infection |
Phase II |
|
|
|
|
|
|
|
|
|
[l]
|
labetuzumab |
8127 |
85 (2001) |
47 (2002) |
hMN14 |
CEACIDE™
|
Humanized |
|
|
|
IgG
|
|
CEACAM5 (carcinoembryonic antigen; CEA; CD66e)
[Homo sapiens]
|
Mus musculus |
|
Immunomedics Inc. (Morris Plains NJ USA) |
Colorectal cancers |
Phase I/II |
|
|
|
|
|
|
|
C2043 |
|
[b]
|
lintuzumab |
7580 |
76 (1996) |
38 (1997) |
HuM195, Huma195-gelonin, SGN-33, SGN-70 |
ZAMYL™
SMART™ M195
|
Humanized |
|
|
|
IgG
|
|
CD33 (SIGLEC3; SIGLEC-3; gp67; p67)
[Homo sapiens]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Seattle genetics, Inc. (Bothell WA USA) |
Acute myeloid leukemia (AML) |
Phase III |
|
Sp2/0 mouse myeloma cells (ATCC CRL 1581) |
|
|
|
|
|
|
|
[b]
[32]
|
Autoimmune diseases |
Phase I |
|
Sp2/0 mouse myeloma cells (ATCC CRL 1581) |
|
|
Myelodysplastic syndrome |
Phase II |
|
Sp2/0 mouse myeloma cells (ATCC CRL 1581) |
|
|
matuzumab |
8103 |
88 (2003) |
50 (2003) |
EMD-72000, EMD72000 |
|
Humanized |
|
|
|
IgG1
|
|
EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB), (epitope on external domain)
[Homo sapiens]
|
Mus musculus |
425 |
Merck Serono International S.A. (Geneva Switzerland) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan) |
Treatment Lung cancers |
Phase II |
|
|
|
|
|
|
|
|
|
[c] [k]
[4]
|
Treatment Stomach cancer |
Phase II |
|
|
|
|
mepolizumab |
7876 |
81 (1999) |
43 (2000) |
SB-240563 |
Bosatria®
|
Humanized |
|
|
|
|
|
IL5 (interleukin 5; IL-5)
[Homo sapiens]
|
Mus musculus |
|
Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) |
Asthma |
Phase II |
|
|
|
|
|
|
|
|
|
[a]
|
Atopic dermatitis |
Phase II |
|
|
|
|
Hypereosinophilic syndrome (HES) |
Phase III |
|
|
|
|
milatuzumab |
8922 |
98 (2007) |
60 (2008) |
MEDI-115, hLL1 |
|
Humanized |
|
8922 |
|
IgG1
|
|
CD74 (major histocompatibility complex class II invariant chain)
[Homo sapiens]
|
Mus musculus |
|
MedImmune Inc. (Gaithersburg MD USA) |
Multiple myeloma |
|
|
|
|
|
|
|
|
|
|
|
motavizumab |
8693 |
95 (2006) |
57 (2007) |
MEDI-524 |
NUMAX®
|
Humanized |
|
8693 |
|
IgG1κ
|
|
RSV (respiratory syncytial virus)
F glycoprotein (fusion protein)
|
Mus musculus |
|
MedImmune Inc. (Gaithersburg MD USA) |
Prevention Respiratory Syncytial Virus (RSV) disease |
Phase III |
|
|
|
|
|
|
|
|
|
[p]
|
natalizumab |
7716 |
79 (1998) |
41 (1999) |
AN 100226 |
TYSABRI®
ANTEGREN® (formerly)
|
Humanized |
|
|
|
IgG4
|
|
INTEGRIN-ALPHA-4_BETA-1, α4β1, VLA4, VCAM1 receptor
[Homo sapiens]
|
Mus musculus |
AN100226m |
Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) |
Acute and chronic inflammatory condtions |
|
|
COS cells transient expression |
|
|
(BLA) 125104 |
|
|
|
869 |
[a] [b] [c] [e] [j] [k]
(3) (4)
[7]
|
Colitis |
Phase II |
|
|
|
|
Crohn's disease (CD) |
Phase M |
FDA approval January 2008 |
NSO mouse myeloma cells |
Therapeutic |
Unknown |
Multiple sclerosis (MS) |
Phase M |
FDA SBLA reintroduced June 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 2005, FDA approval November 2004 |
NSO mouse myeloma cells |
Therapeutic |
Immunology |
nimotuzumab |
8545 |
94 (2005) |
56 (2006) |
Theraloc, hR3 |
THERACIM®
(India, China, Cuba, Argentina, Columbia)
|
Humanized |
|
|
|
IgG1κ
|
|
EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB)
[Homo sapiens]
|
Mus musculus |
|
YM BioScienecs Inc. (Mississauga Canada) |
Glioma cancers |
Phase M |
EMEA withdrawal December 2008, EMEA Orphan drug September 2004 |
NSO mouse myeloma cells |
Therapeutic |
Unknown |
|
|
|
C2733 |
|
[n]
|
Head cancers |
Phase M |
|
NSO mouse myeloma cells |
Therapeutic |
Unknown |
Lung cancers |
Phase II |
|
|
|
|
Metastatic pancreatic cancers |
Phase II |
|
|
|
|
Neck cancers |
Phase M |
|
NSO mouse myeloma cells |
Therapeutic |
Unknown |
Pancreatic cancers |
Phase M |
EMEA Orphan drug June 2008 |
NSO mouse myeloma cells |
Therapeutic |
Unknown |
ocrelizumab |
8636 |
94 (2005) |
56 (2006) |
2H7 |
|
Humanized |
|
|
|
IgG1
|
|
MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35)
[Homo sapiens]
|
Mus musculus |
|
Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) |
Lupus nephritis |
Phase III |
|
|
|
|
|
|
|
C66250 |
|
|
Multiple sclerosis (MS) (relapsing remitting) |
Phase II |
|
|
|
|
Rheumatoid arthritis (RA) |
Phase III |
|
|
|
|
Systemic lupus erythematosus (SLE) |
Phase III |
|
|
|
|
omalizumab |
8039 |
84 (2000) |
46 (2001) |
IGE25, olizumab, rhuMab-E25 |
XOLAIR®
|
Humanized |
|
|
|
IgG1κ
|
|
IgE, CH3
[Homo sapiens]
|
Mus musculus |
MaE11 |
Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) |
Allergic asthma |
Phase M |
|
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Immunology |
(BLA) 103976 |
|
|
C29299 |
|
[a] [b] [l]
|
Severe persistent asthma |
Phase M |
FDA approval (for subcutaneous use) June 2003 |
CHO (Chinese Hamster Ovary) cells |
Therapeutic |
Immunology |
oportuzumab monatox |
9045 |
100 (2008) |
62 (2009) |
VB4-845 |
PROXINIUM™
VICINIUM™
|
Humanized Immunotoxin |
Pseudomonas aeruginosa exotoxin A |
9045 |
|
scFv
|
|
EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM)
[Homo sapiens]
|
Homo sapiens |
|
Viventia Biotechnologies Inc. (Mississauga ON Canada) |
Bladder cancers |
Phase II |
FDA Orphan drug (US) February 2005 |
|
|
|
|
|
|
|
|
|
Head cancers |
Phase II/III |
FDA Orphan drug (US) February 2005 |
|
|
|
Neck cancers |
Phase II/III |
FDA Orphan drug (US) February 2005 |
|
|
|
otelixizumab |
8864 |
98 (2007) |
60 (2008) |
ChAglyCD, TRX4 |
|
Chimeric Humanized |
|
8864 |
|
IgG1
|
|
CD3E (CD3 epsilon; Leu-4)
[Homo sapiens]
|
Rattus sp. |
|
TolerRx (Cambridge CA USA) |
Psoriatic arthritis (PSA) |
|
|
|
|
|
|
|
|
|
|
|
palivizumab |
7753 |
79 (1998) |
41 (1999) |
MEDI-493 |
SYNAGIS®
|
Humanized |
|
|
2hwz |
IgG1κ
|
|
RSV (respiratory syncytial virus)
F glycoprotein (fusion protein)
|
Mus musculus |
|
Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) |
Respiratory Syncytial Virus (RSV) disease (prophylaxis of lower respiratory tract disease in pediatric patients) |
Phase M |
AMM Market authorization (Abbott) August 1999, FDA approval June 1998 |
NSO mouse myeloma cells |
Therapeutic |
Pulmonary, Respiratory diseases |
(BLA) 103770 |
|
|
C2625 |
447 |
[a] [b] [d] [j]
[49]
|
pascolizumab |
8227 |
87 (2002) |
49 (2003) |
SB-240683 |
|
Humanized |
|
|
|
|
|
IL4 (interleukin 4; IL-4)
[Homo sapiens]
|
Mus musculus |
|
Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) |
Allergy |
Phase II |
|
|
|
|
|
|
|
|
|
[a]
|
Asthma |
Phase II |
|
|
|
|
pertuzumab |
8380 |
89 (2003) |
51 (2004) |
rhuMAB 2C4 |
OMNITARG™
|
Humanized |
|
8380 |
1l7i 1s78 |
IgG1κ
|
|
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) |
Breast cancers |
Phase III |
|
|
|
|
|
|
|
C38692 |
|
|
Prostate cancers |
Phase II |
|
|
|
|
pexelizumab |
8153 |
85 (2001) |
47 (2002) |
5G1.1-SC |
|
Humanized |
|
|
|
scFv
|
|
C5 (complement 5)
[Homo sapiens]
|
Mus musculus |
|
Alexion Pharmaceuticals Inc. (New Haven CT USA) |
Cardiopulmonary bypass |
Phase III |
|
|
|
|
|
|
|
|
|
[a]
|
Myocardial infarction |
Phase II |
|
|
|
|
ranibizumab |
8313 |
90 (2004) |
52 (2004) |
Fab-12 variant Y0317, RhuFab |
LUCENTIS®
|
Humanized |
|
8313 |
1cz8 |
Fab
|
|
VEGF-A (Vascular Endothelial Growth Factor A)
[Homo sapiens]
|
Mus musculus |
muMAb-VEGF A.4.6.1 |
Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) |
Neovascular (wet) age related macular degeneration (AMD) |
Phase M |
FDA approval June 2006 |
E.coli (Escherichia coli) |
Therapeutic |
Ophthalmology |
(BLA) 125156 |
|
|
|
904 |
|
ruplizumab |
8014 |
83 (2000) |
45 (2001) |
BG-9588, hu5c8 |
Antova™
|
Humanized |
|
|
|
IgG1κ
|
|
CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein)
[Homo sapiens]
|
Mus musculus |
|
Biogen IDEC Pharmaceuticals (Cambridge MA USA) |
Allograft rejection |
Phase I/II |
|
|
|
|
|
|
|
|
|
[a]
|
Systemic lupus erythematosus (SLE) |
Phase II |
|
|
|
|
siplizumab |
8251 |
87 (2002) |
49 (2003) |
MEDI-507 |
|
Humanized |
|
|
|
|
|
CD2 (LFA-2, Lymphocyte function antigen 2)
[Homo sapiens]
|
Rattus sp. |
BT1-322 |
BioTransplant (Charlestown MA USA) / MedImmune Inc. (Gaithersburg MD USA) |
Acute kidney transplant rejection |
Phase I/II |
|
|
|
|
|
|
|
|
|
[a] [b]
|
Graft-versus-host disease (GvHD) |
Phase II |
|
|
|
|
MedImmune Inc. (Gaithersburg MD USA) |
Psoriasis |
Phase II |
|
|
|
|
solanezumab |
9097 |
100 (2008) |
62 (2009) |
LY2062430 |
|
Humanized |
|
9097 |
|
IgG1κ
|
|
Amyloid-beta (Abeta) peptide soluble monomer
[Homo sapiens]
|
Homo sapiens |
|
Eli Lilly (Indianapolis IN USA) |
Alzheimer's disease |
Phase II |
|
|
|
|
|
|
|
|
|
|
sontuzumab |
8438 |
94 (2005) |
56 (2006) |
AS1402, huHMFG-1 |
|
Humanized |
|
|
|
IgG1
|
|
MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin)
[Homo sapiens]
Episialin
[Homo sapiens]
|
Mus musculus |
|
Antisoma (London UK) |
Breast cancers |
Phase I |
|
|
|
|
|
|
|
|
|
|
tadocizumab |
8651 |
94 (2005) |
56 (2006) |
C4G1, YM-337 |
|
Humanized |
|
8651 |
|
IgG1
|
|
CD41/CD61, INTEGRIN-ALPHA-IIb_BETA-3, αIIbβ3, GPIIbIIIa, Fibrinogen receptor, platelet
[Homo sapiens]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Yamanouchi USA (White Plains NY USA) |
Platelet aggregation |
Phase II |
|
|
|
|
|
|
|
|
|
[b]
|
tanezumab |
8941 |
99 (2008) |
61 (2009) |
RN624 |
|
Humanized |
|
8941 |
|
IgG2
|
|
NGF (nerve growth factor; NGFB, beta polypeptide)
[Homo sapiens]
|
Mus musculus |
|
Pfizer (New York NY USA) |
Chronic pain |
Phase II |
|
|
|
|
|
|
|
|
|
|
Severe acute |
Phase II |
|
|
|
|
teplizumab |
8869 |
97 (2007) |
59 (2008) |
MGA031, hOKT3-gamma-1 (Ala-Ala), humanized OKT3 |
|
Humanized |
|
8869 |
|
IgG1κ
|
|
CD3E (CD3 epsilon; Leu-4)
[Homo sapiens]
|
Mus musculus |
OKT3 |
MacroGenics Inc. (Rockville MD USA) |
Type 1 diabetes |
Phase I/II |
|
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells, COS-1 cells transient expression and larger scale preparation in roller bottles |
|
|
|
|
|
|
|
[c]
[37]
|
tigatuzumab |
8979 |
98 (2007) |
60 (2008) |
CS-1008, TRA-8 |
|
Humanized |
|
8979 |
|
IgG1
|
|
TNFRSF10B (tumor necrosis factor receptor superfamily member 10B; DR5, death receptor 5; TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2; TR-2; CD262)
[Homo sapiens]
|
Mus musculus |
|
Daiichi Sankyo Inc. (Parsippany NJ USA) |
Unknown |
|
|
|
|
|
|
|
|
|
|
|
tocilizumab |
8394 |
90 (2004) |
52 (2004) |
MRA, atlizumab, rhPM-1 |
ACTEMRA™
RoACTEMRA®
(EU)
|
Humanized |
|
|
|
IgG1κ
|
|
IL6R (interleukin 6 receptor; IL-6R)
[Homo sapiens]
|
Mus musculus |
|
Chugai pharmaceuticals Co. Ltd. (Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) |
Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) |
Phase III |
NDA approval April 2005 |
CHO (Chinese Hamster Ovary) DHFR cells |
|
|
|
H-C-955 |
L04AC07 |
|
|
[c]
(5)
[38]
|
Multiple myeloma |
|
|
CHO (Chinese Hamster Ovary) DHFR cells |
|
|
Rheumatoid arthritis (RA) |
Phase III |
EMEA approval November 2008 |
CHO (Chinese Hamster Ovary) DHFR cells |
Therapeutic |
Unknown |
toralizumab |
8232 |
87 (2002) |
49 (2003) |
E6040, IDEC-131 |
|
Humanized |
|
|
|
|
|
CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein)
[Homo sapiens]
|
Mus musculus |
|
Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Eisai Co. Ltd. (Tokyo Japan) |
Multiple sclerosis (MS) |
Phase II |
|
|
|
|
|
|
|
|
|
[a] [b]
|
Systemic lupus erythematosus (SLE) |
Phase I |
|
|
|
|
trastuzumab |
7637 |
78 (1997) |
40 (1998) |
4D5V8, Herceptin |
HERCEPTIN®
|
Humanized |
|
7637 |
1n8z |
IgG1κ
|
|
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2)
[Homo sapiens]
|
Mus musculus |
4D5 |
F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) |
Breast cancers (as adjuvant) |
Phase III |
|
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells |
|
|
(BLA) 103792 |
|
|
C1647 |
485 |
[a] [b] [d] [e] [j]
[48]
|
Metastatic breast cancers overexpressing ERBB2 |
Phase M |
AMM Market authorization (Roche) August 2000, FDA approval October 1998 |
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells |
Therapeutic |
Oncology |
Non-small-cell lung cancers |
Phase II |
|
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells |
|
|
tucotuzumab celmoleukin |
8652 |
94 (2005) |
56 (2006) |
EMD 273066, KSA-Interleukin-2, huKS-IL2 |
|
Humanized |
|
|
|
IgG1
|
mAb huKS - interleukin 2 |
EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM)
|
|
|
Merck Serono International S.A. (Geneva Switzerland) |
Ovarian cancers |
Phase II |
|
|
|
|
|
|
|
|
|
|
Small cell lung cancers (SCLC) |
Phase II |
|
|
|
|
vedolizumab |
9093 |
100 (2008) |
62 (2009) |
LDP-02, LDP02, MLN-02, MLN0002, MLN02 |
|
Humanized |
|
9093 |
|
IgG1κ
|
|
INTEGRIN-ALPHA-4_BETA-7, α4β7, LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)
[Homo sapiens]
|
Homo sapiens |
|
MRC Technology (UK) / Genentech Inc. (S. San Francisco CA USA) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) |
Inflammatory bowel disease (IBD) |
Phase II |
|
|
|
|
|
|
|
|
|
[a] [b] [k]
|
Ulcerative colitis |
Phase II |
|
|
|
|
veltuzumab |
8932 |
98 (2007) |
60 (2008) |
IMMU-106, hA20 |
|
Humanized |
|
8932 |
|
IgG1
|
|
MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35)
[Homo sapiens]
|
Mus musculus |
|
MedImmune Inc. (Gaithersburg MD USA) |
Non-Hodgkin's lymphoma (NHL) |
Phase I |
|
|
|
|
|
|
|
|
|
|
visilizumab |
8054 |
84 (2000) |
46 (2001) |
HuM291 |
NUVION®
SMART™ anti-CD3
|
Humanized |
|
|
|
IgG2
|
|
CD3E (CD3 epsilon; Leu-4)
[Homo sapiens]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Allograft rejection |
Phase I/II |
|
|
|
|
|
|
|
C2687 |
|
[a] [b]
|
Autoimmune diseases |
Phase I |
|
|
|
|
Intravenous steroid-refractory ulcerative colitis (IVSR-UC) |
Phase I/II |
|
|
|
|
Kidney transplantation |
Phase II |
|
|
|
|
Psoriasis |
Phase I/II |
|
|
|
|
yttrium (90Y) tacatuzumab tetraxetan |
8484 |
91 (2004) |
55 (2006) |
hAFP-31 |
|
Humanized |
radiolabelled with Yttrium-90, Y-90 |
|
|
IgG1
|
|
Alpha fetoprotein (α-fetoprotein)
[Homo sapiens]
|
Mus musculus |
|
Unknown |
Unknown |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.5B, 0.5beta |
|
Humanized |
|
|
|
IgG1
|
|
HIV-1 (human immunodeficiency virus), IIIB gp120 V3 loop
[virus]
|
Mus musculus |
|
MRC Technology (UK) / Kaketsuken (Kumamoto Japan) |
Prevention and treatment AIDS, HIV infection |
Preclinical |
|
COS cells transient expression |
|
|
|
|
|
|
|
[c] [k]
(1)
[1]
|
|
|
|
|
15 |
|
Humanized |
|
|
|
|
|
4F2, CD98hc (CD98 heavy chain), FRP-1 (fusion regulatory protein 1)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Merck KgaA (Darmstadt Germany) |
Cancers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1B4 |
|
Humanized |
|
|
|
IgG4
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Mus musculus |
|
Merck & Co., Inc. (Whitehouse Station NJ USA) / NIH (Bethesda MD USA) |
Acute inflammatory disease |
|
|
CV1P cells |
|
|
|
|
|
|
|
[c]
[2]
|
|
|
|
|
3α4D10 |
|
Humanized |
|
|
|
IgG1
|
|
Toxin, (epitope ARGFAK)
[Clostridium perfringens]
|
Mus musculus |
|
Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) |
Gas gangrene |
|
|
YB2/0 rat myeloma cells |
|
|
|
|
|
|
|
[c]
[3]
|
|
|
|
|
4D5, DOTA-4D5 conjugated |
|
Humanized |
radiolabelled with Yttrium-90, Y-90 radiolabelled with Indium-111, In-111 |
|
|
IgG1κ
|
|
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2), extracellular domain
[Homo sapiens]
|
Mus musculus |
4D5 |
Genentech Inc. (S. San Francisco CA USA) |
Breast cancers (overexpressing ERBB2) |
|
|
Adenovirus transformed human embryonic 293 kidney cells |
|
|
|
|
|
|
|
[c]
[47]
|
Ovarian cancers (overexpressing ERBB2) |
|
|
Adenovirus transformed human embryonic 293 kidney cells |
|
|
|
|
|
|
5c8 |
|
Humanized |
|
|
|
|
|
CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Biogen IDEC Pharmaceuticals (Cambridge MA USA) |
Autoimmune diseases |
|
|
|
|
|
|
|
|
|
|
[k]
|
Inflammation |
|
|
|
|
|
|
|
|
|
60,3 |
|
Humanized |
|
|
|
IgG1
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Mus musculus |
|
Bristol-Myers Squibb (Princeton NJ USA) |
Myocardial infarction |
|
|
Ag8.653 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
(2)
[5]
|
|
|
|
|
7F11C7, CTM01 |
|
Humanized |
|
|
|
IgG4
|
|
MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) |
Breast cancers |
|
|
|
|
|
|
|
|
|
|
[c]
(6) (7)
[18]
|
Ovarian cancers |
|
|
NSO mouse myeloma cells, Transient in CHO (Chinese Hamster Ovary) L761h cells |
|
|
|
|
|
|
A4.6.1 |
|
Humanized |
|
|
|
IgG1
|
|
VEGF (Vascular Endothelial Growth Factor)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) |
Cancers |
|
|
E.coli (Escherichia coli) |
|
|
|
|
|
|
|
[c]
[6]
|
|
|
|
|
ABC-48, CY-174 |
|
Humanized |
|
|
|
|
|
SELP (P-selectin; CD62P)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Cytel Corporation (San Diego CA USA) |
Inflammation |
Preclinical |
|
|
|
|
|
|
|
|
|
[k]
|
|
|
|
|
ABC-88, CY-178 |
|
Humanized |
|
|
|
|
|
SELE (E-selectin; CD62E)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Cytel Corporation (San Diego CA USA) |
Inflammation |
|
|
|
|
|
|
|
|
|
|
[k]
|
|
|
|
|
AD-159 |
|
Humanized |
|
|
|
|
|
HIV (human immunodeficiency virus), gp120
[virus]
|
Mus musculus |
|
Tanox Inc. (Houston TX USA) |
AIDS, HIV infection |
Phase I/II |
|
|
|
|
|
|
|
|
|
[a]
|
|
|
|
|
AD-439 |
|
Humanized |
|
|
|
|
|
HIV (human immunodeficiency virus), gp120 V3 loop
[virus]
|
Mus musculus |
|
Tanox Inc. (Houston TX USA) |
AIDS, HIV infection |
Phase II |
|
|
|
|
|
|
|
|
|
[a] [e]
|
|
|
|
|
AS1409, BC1-IL12, huBC1-huIL12 |
|
Humanized |
|
|
|
|
mAb huBC1 - interleukin 12 |
ED-B (extra domain B) of fibronectin
[Homo sapiens]
|
|
|
Antisoma (London UK) |
Melanoma |
Phase I |
|
|
|
|
|
|
|
|
|
|
Renal cancers |
Phase I |
|
|
|
|
|
|
|
|
AT13/5 |
|
Humanized |
|
|
|
IgG1
|
|
CD38
[Homo sapiens]
|
Mus musculus |
|
Tenovus Research (UK) / Wellcome (London UK) |
Multiple myeloma |
|
|
CHO (Chinese Hamster Ovary) cells, NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[8]
|
|
|
|
|
AUK12-20 |
|
Humanized |
|
|
|
IgG1
|
|
IL6R (interleukin 6 receptor; IL-6R)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Chugai pharmaceuticals Co. Ltd. (Japan) / Osaka University Medical School (Osaka Japan) |
IL6 dependent tumors |
|
|
COS cells transient expression |
|
|
|
|
|
|
|
[c] [k]
(5)
[9]
|
|
|
|
|
Anti-TAC 90 Υ-HAT |
|
Humanized |
radiolabelled with Yttrium-90, Y-90 |
|
|
|
|
|
Mus musculus |
|
National Cancer Institute (Bethesda MD USA) |
Lymphoma |
Phase I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BAT |
STIMUMAB™
|
Humanized |
|
|
|
IgG1
|
|
T cell transmembrane protein
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / CureTech (Yavne Israel) |
Cancers |
Preclinical |
|
|
|
|
|
|
|
|
|
[k]
|
|
|
|
|
BAY 103356, BAY W 3356, CDP571 |
Humicade™
|
Humanized |
|
|
|
IgG4
|
|
TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) |
Crohn's disease (CD) |
Phase II |
|
|
|
|
|
|
|
|
|
[a]
|
Rheumatoid arthritis (RA) |
Phase II |
|
|
|
|
|
|
|
|
BC-1 |
|
Humanized |
|
|
|
|
|
ED-B (extra domain B) of fibronectin
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Antisoma (London UK) |
Angiogenesis |
Preclinical |
|
|
|
|
|
|
|
|
|
[k]
[51]
|
|
|
|
|
BIW-8405, MEDI-563 |
|
Humanized |
|
|
|
IgG1
afucosylated
|
|
IL5RA (interleukin 5 receptor alpha)
[Homo sapiens]
|
|
|
MedImmune Inc. (Gaithersburg MD USA) |
Asthma |
Phase II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BMA 031 |
|
Humanized |
|
|
|
IgG1
|
|
TRαβ (T cell receptor alpha/beta)
[Homo sapiens]
|
Mus musculus |
|
Behringwerke Aktiengesellschaft (Marburg Germany) / Genzyme Corp. (Cambridge MA USA) |
Autoimmunity |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[13]
|
Graft-versus-host disease (GvHD) |
|
|
Sp2/0 mouse myeloma cells |
|
|
Transplantation |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
BW431/26 |
|
Humanized |
|
|
|
IgG3
|
|
CEACAM5 (carcinoembryonic antigen; CEA; CD66e)
[Homo sapiens]
|
Mus musculus |
|
Behringwerke Aktiengesellschaft (Marburg Germany) / MRC Laboratory of Molecular Biology (Cambridge UK) |
Treatment Breast cancers |
|
|
BHK cells (ATCC CCL 10) |
|
|
|
|
|
|
|
[c]
[15]
|
Treatment Colorectal cancers |
|
|
BHK cells (ATCC CCL 10) |
|
|
Treatment Lung cancers |
|
|
BHK cells (ATCC CCL 10) |
|
|
|
|
|
|
BrE-3 |
|
Humanized |
|
|
|
IgG1
|
|
MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin)
[Homo sapiens]
|
Mus musculus |
|
Cancer Research Fund of Contra Costa (Walnut Creek CA USA) / NIH (Bethesda MD USA) |
Breast cancers |
|
|
Sp2/0-Ag14 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[16]
|
|
|
|
|
C21/AL-90, HU-901, TNX-901 |
|
Humanized |
|
|
|
|
|
IgE
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Novartis (Basel Switzerland) / Tanox Inc. (Houston TX USA) |
Peanut allergy (severe) |
Phase II |
|
|
|
|
|
|
|
|
|
[b] [k] [l]
|
|
|
|
|
CAMPATH-9 |
|
Humanized |
|
|
|
|
|
CD4 (p55)
[Homo sapiens]
|
Rattus sp. |
|
Pathology Dept., University of Cambridge (Cambridge UK) |
Establishment of immunological tolerance state |
|
|
CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells |
|
|
|
|
|
|
|
[c]
[20]
|
|
|
|
|
CC49 |
|
Humanized |
|
|
|
IgG1
|
|
TAG 72 (tumour associated glycoprotein 72)
[Homo sapiens]
|
Mus musculus |
|
NIH (Bethesda MD USA) |
Cancers |
|
|
Sp2/0 mouse myeloma cells |
Diagnostic, Therapeutic |
Unknown |
|
|
|
|
|
[c] [e]
[17]
|
|
|
|
|
CDP850 |
|
Humanized |
|
|
|
|
|
SELE (E-selectin; CD62E)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) |
Psoriasis |
Phase I |
|
|
|
|
|
|
|
|
|
[a]
|
|
|
|
|
CE25/B7 |
|
Humanized |
|
|
|
|
|
CEACAM5 (carcinoembryonic antigen; CEA; CD66e)
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) |
Cancers |
|
|
|
|
|
|
|
|
|
|
[k]
|
|
|
|
|
Fd138-80 |
|
Humanized |
|
|
|
IgG1
|
|
HSV (herpes simple virus), gD glycoprotein
[virus]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) |
Neutralisation activity of HSV-1 |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[24]
|
|
|
|
|
Fd79 |
|
Humanized |
|
|
|
IgG1
|
|
HSV (herpes simple virus), gB glycoprotein
[virus]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) |
Neutralisation activity of HSV-1 |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[24]
|
|
|
|
|
H17E2 |
|
Humanized |
|
|
|
IgG1
|
|
PLAP-like testicular alkaline phosphatase
[Homo sapiens]
PLAP (placental alkaline phosphatase; EC 3.1.3.1)
[Homo sapiens]
|
Mus musculus |
|
Unilever (UK) |
Treatment Ovarian cancers |
|
|
NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[25]
|
Treatment Testicular cancers |
|
|
NSO mouse myeloma cells |
|
|
|
|
|
|
H52 |
|
Humanized |
|
|
|
IgG1
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) |
Potential to ameliorate deleterious immunological and inflammatory processes |
|
|
E.coli (Escherichia coli) |
|
|
|
|
|
|
|
[c]
[26]
|
|
|
|
|
HCMV16 |
|
Humanized |
|
|
|
IgG1
|
|
HCMV (human cytomegalovirus), gH envelope glycoprotein
[virus]
|
Mus musculus |
|
Royal Free Hospital School of Medicine (London UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) |
Prevention and treatment Human cytomegalovirus (HCMV) (infections in immunocompromised patients (Passive immunisation either alone or in combination with antiviral agents)) |
|
|
NSO mouse myeloma cells, YB2/0 rat myeloma cells |
|
|
|
|
|
|
|
[c]
[27]
|
|
|
|
|
HCMV37 |
|
Humanized |
|
|
|
IgG1
|
|
HCMV (human cytomegalovirus), gB envelope glycoprotein
[virus]
|
Mus musculus |
|
Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) |
Human cytomegalovirus (HCMV) (Herpes infections in immunocompromised individuals) |
|
|
YB2/0 rat myeloma cells |
|
|
|
|
|
|
|
[c]
[28]
|
|
|
|
|
HMFG1 |
|
Humanized |
|
|
|
IgG1
|
|
MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin), (epitope PDTR)
[Homo sapiens]
|
Mus musculus |
|
The Netherlands CRC Labs (Nottingham UK) / Unilever (UK) |
Neoplasms of epithelial origin, particularly carcinomas of breast, ovary, cervix, bronchus, and gastrointestinal tract |
|
|
NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
(7)
[29]
|
|
|
|
|
Hu23F2G |
LEUKARREST™
|
Humanized |
|
|
|
|
|
|
Mus musculus |
|
ICOS Corporation (Bothell WA USA) |
Ischemic stroke |
Phase III |
|
|
|
|
|
|
|
|
|
[b]
|
|
|
|
|
ICM3 |
|
Humanized |
|
|
|
|
|
ICAM3 (intercellular adhesion molecule 3; CD50; ICAM-3)
[Homo sapiens]
|
Mus musculus |
|
ICOS Corporation (Bothell WA USA) |
Psoriasis |
Phase I/II |
|
|
|
|
|
|
|
|
|
[a]
|
|
|
|
|
JES1-39D10 |
|
Humanized |
|
|
|
IgG4
|
|
IL5 (interleukin 5; IL-5)
[Homo sapiens]
|
Rattus sp. |
|
Schering-Plough (Kenilworth NJ USA) / University of Alabama (Tuscaloosa AL USA) |
IL5 induced eosinophils diseases (eg asthma) |
|
|
COS cells transient expression |
|
|
|
|
|
|
|
[c]
[30]
|
|
|
|
|
KB001 |
HUMANEERED™
|
Humanized |
|
|
|
Fab'
|
|
PcrV (located at the tip of the syringe-like TTSS (Type Three Secretion System))
[virus]
|
Mus musculus |
|
KaloBios Pharmaceuticals Inc. (Palo Alto CA USA) |
Pseudomonas aeruginosa infections |
Phase I/II |
|
|
|
|
|
|
|
|
|
[p]
|
|
|
|
|
LDP-01, MLNM2201 |
|
Humanized |
|
|
|
IgG
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Mus musculus |
|
Millennium Pharmaceuticals Inc. (Cambridge MA USA) |
Allograft rejection (in kidney transplantation) |
|
|
|
|
|
|
|
|
|
|
[a] [b]
|
Stroke |
Phase I/II |
|
|
|
|
|
|
|
|
M22 |
|
Humanized |
|
|
|
IgG1
|
|
FCGR1 (FCGR1A, FCGR1B, FCGR1C) (Fc gamma RI; CD64)
[Homo sapiens]
|
Mus musculus |
|
Dartmouth Medical School (Hanover NH USA) / Medarex (Princeton NJ USA) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) |
Immunotherapy directed against human high affinity receptor for the Fc portion of IgG |
|
|
NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[33]
|
|
|
|
|
M4 |
|
Humanized |
|
|
|
IgG1
|
|
TAG 72 (tumour associated glycoprotein 72), (epitope sialosyl-Tn)
[Homo sapiens]
|
Mus musculus |
|
University of Saskatchewan (Saskatchewan Canada) |
Colorectal cancers |
|
|
Sp2/0-Ag14 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[12]
|
Gastric cancers |
|
|
Sp2/0-Ag14 mouse myeloma cells |
|
|
Ovarian cancers |
|
|
Sp2/0-Ag14 mouse myeloma cells |
|
|
|
|
|
|
MDX-CD4 |
|
Humanized |
|
|
|
IgG
|
|
CD4 (p55)
[Homo sapiens]
|
Mus musculus |
|
Eisai Co. Ltd. (Tokyo Japan) / Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) |
Rheumatoid arthritis (RA) |
Phase I |
|
|
|
|
|
|
|
|
|
[a]
|
|
|
|
|
ME361 |
|
Humanized |
|
|
|
|
|
GD2 ganglioside
[Homo sapiens]
|
Mus musculus |
|
MRC Technology (UK) / Merck KgaA (Darmstadt Germany) |
Cancers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MEDI-528 |
|
Humanized |
|
|
|
IgG1
|
|
IL9 (interleukin 9; IL-9)
[Homo sapiens]
|
|
|
MedImmune Inc. (Gaithersburg MD USA) |
Asthma |
Phase II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MK-0646 |
|
Humanized |
|
|
|
IgG1
|
|
IGF1R (insulin-like growth factor 1 receptor; IGF-1R; CD221)
[Homo sapiens]
|
|
|
Merck & Co., Inc. (Whitehouse Station NJ USA) |
Solid tumors |
Phase I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MaE11 |
|
Humanized |
|
|
|
IgG1
|
|
IgE
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) |
IgE mediated allergies |
|
|
Adenovirus transformed human embryonic 293 kidney cells |
|
|
|
|
|
|
|
[c]
[34]
|
|
|
|
|
MikB1 |
|
Humanized |
|
|
|
IgG1
|
|
IL2RB (interleukin-2 receptor, beta; IL-2R; p70; CD122)
[Homo sapiens]
|
Mus musculus |
|
F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Kyoto-Katsura Hospital (Kyoto Japan) / National Cancer Institute (Bethesda MD USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Prevention Allograft rejection (in conjunction with humanized anti-Tac) |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[35]
|
Autoimmune diseases |
|
|
Sp2/0 mouse myeloma cells |
|
|
Graft-versus-host disease (GvHD) |
|
|
Sp2/0 mouse myeloma cells |
|
|
|
|
|
|
PRO542 |
|
Humanized |
|
|
|
|
|
HIV (human immunodeficiency virus), gp120
[virus]
|
Mus musculus |
|
Genzyme Corp. (Cambridge MA USA) / Progenics Pharmaceuticals Inc. (Tarrytown NY USA) |
AIDS, HIV infection |
Phase I/II |
|
|
|
|
|
|
|
|
|
[a]
|
|
|
|
|
RSV19 |
|
Humanized |
|
|
|
IgG1
|
|
RSV (respiratory syncytial virus), fusion protein (F glycoprotein)
[virus]
|
Mus musculus |
|
AFRC Inst. Animal Health (UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) |
Respiratory Syncytial Virus (RSV) disease (acute respiratory illness in young children) |
|
|
YB2/0 rat myeloma cells (from ATCC) |
|
|
|
|
|
|
|
[c]
[39]
|
|
|
|
|
SCH55700 |
|
Humanized |
|
|
|
|
|
IL5 (interleukin 5; IL-5)
[Homo sapiens]
|
Mus musculus |
|
Celltech, UCB (Brussels Belgium) / Schering AG (Berlin Germany) |
Allergy |
Phase I |
|
|
|
|
|
|
|
|
|
[a]
|
Asthma |
Phase I |
|
|
|
|
|
|
|
|
SK2 |
|
Humanized |
|
|
|
IgG1
|
|
IL6 (interleukin 6; IL-6)
[Homo sapiens]
|
Mus musculus |
|
Chugai pharmaceuticals Co. Ltd. (Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
AIDS, HIV infection |
|
|
CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression |
|
|
|
|
|
|
|
[c]
[40]
|
Cardiac myxoma |
|
|
CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression |
|
|
Increased levels of IL6 in sepsis |
|
|
CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression |
|
|
Rheumatoid arthritis (RA) |
|
|
CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression |
|
|
|
|
|
|
T84.66 M5A, hT84.66 |
|
Humanized |
|
|
|
|
|
CEACAM5 (carcinoembryonic antigen; CEA; CD66e)
[Homo sapiens]
|
Mus musculus |
T84.66 |
Beckman Research Institute (Duarte CA USA) |
Metastatic colorectal cancers |
|
|
|
|
|
|
|
|
|
|
[p]
[58]
|
|
|
|
|
TES-C21 |
|
Humanized |
|
|
|
IgG1
|
|
IgE, free and bound to B cells
[Homo sapiens]
|
Mus musculus |
|
Ciba-Geigy AG (Basel Switzerland) / MRC Laboratory of Molecular Biology (Cambridge UK) |
Immediate-type hypersensitivities |
|
|
COS cells transient expression, NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[41]
|
|
|
|
|
XOMA 052 |
|
Humanized |
|
|
|
IgG2
|
|
IL1B (interleukin 1 beta; IL-1B)
[Homo sapiens]
|
Mus musculus |
|
Xoma (Berkeley CA USA) |
Type 2 diabetes |
|
|
|
|
|
|
|
|
|
|
[p]
|
|
|
|
|
YFC51.1 |
|
Humanized |
|
|
|
IgG1
IgG4
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Rattus sp. |
|
Cambridge University (Cambridge UK) / Wellcome (London UK) |
Prevention Influx of leukocytes in Sepsis or reperfusion injury, adult respiratory distress syndrome and graft rejection |
|
|
COS cells transient expression, NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
(2)
[43]
|
|
|
|
|
YTH12.5 |
|
Humanized |
|
|
|
IgG1
|
|
CD3E (CD3 epsilon; Leu-4)
[Homo sapiens]
|
Rattus sp. |
|
Cambridge University (Cambridge UK) |
Autoimmunity |
|
|
CHO (Chinese Hamster Ovary) DHFR cells |
|
|
|
|
|
|
|
[c]
[44]
|
Organ rejection |
|
|
CHO (Chinese Hamster Ovary) DHFR cells |
|
|
T cell lymphoma |
|
|
CHO (Chinese Hamster Ovary) DHFR cells |
|
|
|
|
|
|
anti-B4 |
|
Humanized |
|
|
|
IgG1
|
|
CD19 (B lymphocyte surface antigen B4; Leu-12)
[Homo sapiens]
|
Mus musculus |
|
ImmunoGen Inc. (Cambridge MA USA) / University Bath (Bath UK) |
B cell malignancies |
|
|
COS cells transient expression |
|
|
|
|
|
|
|
[c]
[45]
|
|
|
|
|
anti-CD18 |
|
Humanized |
|
|
|
F(ab')2
|
|
ITGB2 (INTEGRIN-BETA-2; CD18)
[Homo sapiens]
|
Mus musculus |
|
Genentech Inc. (S. San Francisco CA USA) |
Acute myocardial infarction |
Phase II |
|
|
|
|
|
|
|
|
|
[a] [b]
|
|
|
|
|
anti-IL4 |
|
Humanized |
|
|
|
|
|
IL4 (interleukin 4; IL-4)
[Homo sapiens]
|
Mus musculus |
|
PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Asthma |
Phase I |
|
|
|
|
|
|
|
|
|
[b]
|
|
|
|
|
huN901-DM1 |
|
Humanized |
|
|
|
IgG1
|
|
NCAM1 (neural cell adhesion molecule 1; CD56; NCAM-1)
[Homo sapiens]
|
Mus musculus |
|
ImmunoGen Inc. (Cambridge MA USA) / University Bath (Bath UK) |
Small cell lung cancers (SCLC) |
|
|
CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells |
|
|
|
|
|
|
|
[c]
[36]
|
|
|
|
|
humanized B1-8 |
|
Humanized |
|
|
|
IgE
|
|
Hapten NP-cap (4-hydroxy-3-nitrophenacethyl caproic acid)
[Homo sapiens]
NIP-cap (3-iodo-4-hydroxy-5-nitrophenyl-acetyl caproic acid)
[Homo sapiens]
|
Mus musculus |
B1-8 |
MRC Laboratory of Molecular Biology (Cambridge UK) |
Unknown |
Proof of concept |
|
Stably transformed J558L cells |
|
|
|
|
|
|
|
[c]
[10]
|
|
|
|
|
humanized D1.3 |
|
Humanized |
|
|
|
IgG1
IgG2
|
|
Lysozyme
[Homo sapiens]
|
Mus musculus |
D1.3 |
MRC Laboratory of Molecular Biology (Cambridge UK) |
Unknown |
Proof of concept |
|
J558L mouse myeloma cells, NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[21] [22]
|
|
|
|
|
humanized DX48 |
|
Humanized |
|
|
|
IgG1
|
|
Digoxin
[Homo sapiens]
|
Rattus sp. |
DX48 |
Wellcome (London UK) |
Unknown |
Proof of concept |
|
|
|
|
|
|
|
|
|
[c]
[23]
|
|
|
|
|
humanized K20 |
|
Humanized |
|
|
|
IgG1
|
|
ITGB1 (INTEGRIN-BETA-1; CD29)
[Homo sapiens]
|
Mus musculus |
MuK20 |
INSERM (Montpellier France) / LIGM (Montpellier France) |
Immunosuppression |
|
|
Insect cells, NSO mouse myeloma cells |
|
|
|
|
|
|
|
[c]
[31]
|
|
|
|
|
mu-39.1 |
|
Humanized |
|
|
|
|
|
HIV-1 (human immunodeficiency virus)
[virus]
|
Mus musculus |
|
MRC Technology (UK) / Kaketsuken (Kumamoto Japan) |
AIDS, HIV infection |
|
|
|
|
|
|
|
|
|
|
[k]
|
|
|
|
|
|
ALLOMUNE™
|
Humanized |
|
|
|
|
|
CD2 (LFA-2, Lymphocyte function antigen 2)
[Homo sapiens]
|
Mus musculus |
|
BioTransplant (Charlestown MA USA) |
Hodgkin's disease (HD) |
Phase I |
|
|
|
|
|
|
|
|
|
[b]
|
Non-Hodgkin's B cell lymphoma (NHL) (refractory) |
Phase I |
|
|
|
|
|
|
|
|
|
PROTOVIR™
|
Humanized |
|
|
|
IgG1
|
|
HCMV (human cytomegalovirus)
[virus]
|
Mus musculus |
|
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) |
Human cytomegalovirus (HCMV) |
Phase III |
|
|
|
|
|
|
|
|
|
[a]
|